B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

Werewolf Therapeutics, Inc. +5.38%

Werewolf Therapeutics, Inc.

HOWL

1.01

+5.38%

B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ: HOWL) with a Buy and lowers the price target from $8 to $7.